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L. Leon,1 A.D. Giannoukas,2 D. Dodd,2 P. Chan2 and N. Labropoulos1*1Loyola University Medical Center, 2160 South First Avenue, Maywood, IL, USA; and 2Sheffield Vascular
Institute, Northern General Hospital, Herries Road, Sheffield S5 7AU, UKObjective. To evaluate the clinical implications of superficial thrombophlebitis (STP) including its demographic
characteristics, distribution, risk factors, relationship with deep vein thrombosis (DVT), pulmonary embolism (PE),
diagnosis and management.
Methods. Data were collected from relevant papers using aMEDLINE search and an extensive bibliography review. Studies
were considered only when they contained pertinent material to STP. Thirty-seven papers were analysed.
Results. The diversity of patients and methods used in the different studies made the comparison among them difficult. STP
is a common condition with an underestimated prevalence. There are many risk factors associated with STP but the strongest
relation was seen with hypercoagulable states. Malignancy may be another important factor but the strength of this
association remains unknown. Coexistence with DVTwas found in 6–53%. PE occurred in 0–33.3%. Propagation to DVT
ranged from 2.6 to 15%. Treatment has not been standardised and may include elastic compression, anti-inflammatory
drugs, anticoagulation and surgery.
Conclusion. The limited number of prospective randomised studies on STP does not allow strong recommendations to be
given. Although STP most often is perceived as benign, it can coexist with or progress to DVT, and even give rise to PE. It is
also associated with hypercoagulability and malignancy.Keywords: Superficial vein thrombosis; Duplex ultrasonography; Hypercoagulable states; Venous thromboembolism.Introduction
Thrombosis in the superficial veins has been termed
superficial thrombophlebitis (STP) or superficial vein
thrombosis. It is most often found in the veins of the
lower extremities but it has been reported in many
other locations. It has been considered benign, and it is
usually treated conservatively with elastic stockings
(ES), ambulation, antibiotics, and non-steroidal anti-
inflammatory drugs (NSAIDS).1–4 Patients with
thrombosis in proximity to the deep veins have been
treated with ligation or anticoagulation.
STP presents with pain, erythema, and swelling
around a superficial vein that becomes solid and on
palpation feels like a cord. It is most frequently found
in patients with varicose veins, but many other factors
have been associated with this condition.5–10 Althoughing author. Nicos Labropoulos, Associate Professor of
artment of Surgery, Loyola University Medical Center,
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the use of duplex ultrasound imaging (DUS) has
enabled the accurate detection of its extent and
progress.6,11–14
There is evidence in the literature suggesting that
STP is not always benign. It may precipitate or be
associated with deep venous thrombosis (DVT), and it
could cause pulmonary embolism (PE). The strength
of these associations has not been adequately studied,
and there are only a few prospective studies dealing
with this condition. The purpose of this manuscript is
to review the aetiology, characteristics, natural history
and management of STP since such analysis in the
literature is scarce.MethodsLiterature search
A MEDLINE search from 1966 until 2003 (NationalEur J Vasc Endovasc Surg 29, 10–17 (2005)
doi:10.1016/j.ejvs.2004.09.021, available online at http://www.sciencedirect.com onved.
Superficial Vein Thrombosis 11Library of Medicine and OVID) and an extensive
manual search were carried out using bibliographies
from relevant published papers. The main terms for
inclusion were superficial vein thrombosis, throm-
bophlebitis, saphenous thrombosis, varicose vein
thrombosis and other similar terms. Other search
terms relevant to this topic included thromboembo-
lism, malignancy, hypercoagulable states, pregnancy
and management. As there were very few prospective
studies it was decided to also include retrospective
papers. Case reports and very small series (n!15
patients) were excluded. Papers were chosen by their
cohesion and relevance of data. A total of 37 studies
were included in the analysis. The data were analysed
for associated conditions such as DVT, PE, malignancy,
hypercoagulable states and management related to
STP.Limitation
The wide diversity of patients and methods used in
the published reports made comparisons between
them difficult. The small number of prospective
natural history and randomised studies did not
allow robust conclusions to be made or strong
recommendations to be given. Because of these
limitations, the authors considered that pooled anal-
ysis and statistical manipulation of the data would not
be appropriate. Interpretation and analysis was con-
fined to a descriptive report of the selected studies.Demographic characteristics
The incidence of STP has been reported to be 3–11% in
the general population.15 Coon et al.16 reported a rate
of 123,000 patients per year for clinically recognised
STP. Seventy-eight percent of those patients were
female. Both of these epidemiological studies are old
and the diagnosis was clinical. Its prevalence is
probably underestimated because in many patients,
the symptoms of STP can be minor, and patients may
not present for medical attention. Most papers
revealed a preponderance of female sex with a ratio
of 6–4,17–22 possibly because of the increased preva-
lence of varicose veins in pregnancy.22 Risk factors that
have been cited in association with STP include
previous thromboembolic episodes, long-haul flight,
pregnancy, oral contraceptives, hormone replacement
therapy, immobilization, obesity, recent surgery,
trauma and sclerotherapy. Often, two or more risk
factors have to be present for thrombosis to occur
although age is an additional factor; the older thepatient, the fewer factors are needed.23 The mean age
of presentation is approximately 60 years.20,21,24–28Varicose veins, location and STP
Thrombosis in the saphenous veins and their tribu-
taries is the most common location followed by the
cephalic and basilic vein in the upper extremities.
Thrombosis in superficial veins in other parts of the
body is uncommon.20 The prevalence of STP in large
series of patients with varicose veins has a wide range
varying from 4 to 59%.6,18,22 The great saphenous vein
(GSV) is involved in 60–80% of cases, and the small
saphenous vein (SSV) in 10–20%. No predilection for
either lower extremity is found.6 Bilateral cases are
reported in 5–10%6,20 and in one report were associ-
ated with a high number of complications (8%).6
Patients with GSV thrombosis had more complications
than thrombosis in other locations.6 STP was more
frequently found in varicose tributaries rather than in
the saphenous trunk.18 There may also be localised
defects in the processes of fibrinolysis and platelet
aggregation.29 The current evidence is not definitive
and further work is needed.Hypercoagulable states
STP confined to varicose tributaries is a complication
of varicose vein disease. However, saphenous trunk
thrombosis is often a more significant thromboembolic
process.12,24 Abnormalities of coagulation have been
reported to be associated with saphenous thrombosis
including deficiencies of antithrombin III, anticardio-
lipin antibodies, heparin cofactor 2, protein C and S,
abnormal fibrinolytic activity, Hageman trait and the
gene mutations of factor V Leiden and factor II
(prothrombin) G20210A.8,9,24,30 In the absence of
varicose veins, autoimmune diseases or malignancy
the risk of STP was found to be 6-fold for the Factor V
Leiden mutation, 4-fold for the factor II G20210A
mutation and 13-fold for antithrombin III, protein C
and S deficiencies taken together.7 It appears that
anticardiolipin antibodies and increased levels of
factor VIII are more prevalent in patients with
recurrent STP.30,31 There are no large studies evaluat-
ing the prevalence of hypercoagulable states in
different cohorts of patients with STP. However, it is
clear in multiple studies as shown in Table 17,8,24,30–35
that patients with STP have high prevalence of
hypercoagulable states. Arguably, patients with spon-
taneous STP without varicose veins, or extending to
the main trunk of the GSV, should be screened for
hypercoagulability.Eur J Vasc Endovasc Surg Vol 29, January 2005
Table 1. STP and hypercoagulable states
Author Patients State Prevalence (%) Odds ratio (95%
confidence inter-
vals)
STP
Engesser 198732 71 Protein S deficiency 72
Lohr 199233 29 Abnormal coagu-
lation profile
65 – Isolated
Pabinger 199634 230 Coagulation inhibi-
tor deficiency
[ in Protein C and S
deficiency
– First episode and
recurrent
De Moerloose 19988 112 Factor V Leiden 14.3 2.51 (1.04–6.24) First episode
Factor IIA20210 3.6 3.28 (0.46–36.84)
Hanson 199824 17 ATIII 17.6 – First episode
ATIIICProtein S 5.9
Protein S 5.9
Protein SCAPCR 5.9
Martinelli 19997 63 Factor V:A1691 15.9 6.1 (2.6–14.2) First episode
Factor IIG20210A 9.6 4.3 (1.5–12.6)
ATIII, Prot C or S
deficiency
10.2 12.9 (3.6–46.2)
de Godoy 200131 45 Anticardiolipin
antibodies
33.3 6.64 (2.48–17.82) Recurrent
de Godoy 200335 36 Protein S deficiency 5.2 Recurrent (R2)
Schonauer 200330 45 High Factor VIII 24% (pZ0.004) 4 (2.0–8.6) Recurrent VTE
VTE, venous thromboembolism; ATIII, antithrombin III deficiency; APCR, activated protein C resistance.
L. Leon et al.12Pregnancy
There is limited information on the relation of
pregnancy and STP. In one retrospective study invol-
ving 30,040 pregnancies, 14 cases (0.05%) were
diagnosed by ultrasonography, mostly presenting
within 48 h of delivery.36 McColl et al.10 found an
incidence of 0.068% [49/72,200 deliveries; 95% confi-
dence intervals (CI) 0.048–0.088]. Ten cases occurred
prior to delivery and the rest of cases (nZ39, 0.054%,
95% CI 0.037–0.071) within 7 days postpartum. Of the
patients with STP only 24 were tested for thrombo-
philic abnormalities, and only one was positive for a
Factor V Leiden mutation. Both studies have probably
underestimated the prevalence of STP because they
evaluated only symptomatic patients.Malignancy
Patients presenting with significant venous disease
may have an underlying neoplasm. A literature review
on vascular disorders that preceded the diagnosis of
malignancy revealed a weak relationship between STP
and cancer.37 This association was mainly based on
data from two papers from the early 60s, but did not
include two further studies, which also reported an
association. Among 106 limbs with STP the incidence
of malignancy was 13%; in 11 cases the diagnosis was
known at the time of onset of STP, and in three the
diagnosis was made within 1 month.13 In a large study
of 398 limbs with STP in the GSV or SSV, ascending
superficial thrombosis was detected in 56. Ten (18%) ofEur J Vasc Endovasc Surg Vol 29, January 2005these had malignant disease.38 However, apart from
these retrospective studies there is no other evidence
supporting an association between cancer and STP. In
our practice occasionally we find patients with STP
and cancer and usually the latter is diagnosed first.
The strength of this association remains unknown and
needs to be further studied, preferably in cohorts with
defined malignant disease.DVT and STP
The evidence on concomitant STP and DVTand/or PE
is controversial. Most of the studies that we found are
retrospective, and some include very small numbers of
patients. We chose only papers that included at least 20
patients for analysis. The presence of DVT in associ-
ation with saphenous thrombosis ranges from 6 to 53%
(Table 2).6,14,17,18,21,22,25,39–51 Thrombus propagation
can occur in a contiguous and in a non-contiguous
fashion. From 53 patients with clinical manifestations
of STP and diagnosed with DVT, evidence of direct
contiguous propagation was found in 40 cases (75.5%),
and the rest was non-contiguous calf involvement at
the posterior tibial and soleal levels.6 Contiguous
extension of the thrombotic process from the super-
ficial into the deep veins can occur in three ways.41 The
most common involves extension from the GSV into
the femoral vein.6,41 Less often, the thrombus extends
from the SSV into the popliteal vein through the
saphenopopliteal junction (SPJ). Extension through
perforating veins can also occur to several deep
venous structures. From 186 DUS scans with evidence
Table 2. STP and concomitant venous thromboembolism (VTE)
Author Patients (n) DVT (%) PE (%) Diagnosis Treatment
Gervais 195639 64 6 – Surgery* Surgery
Gjores 196240 40 32 5 – Surgery
Zollinger 196221 335 – 10.1 Clinical –
Hafner 196441 133 17 – Surgery* –
Lofgren 198118 163 8 – Clinical Surgery
Husni 198222 139 7† – – Surgery
Plate 198542 28 14 – VNG, VQ Surgery
Bergqvist 198643 56 16 – VNG –
Skillman 199044 42 12 – VNG, SG, DUS Medical
Lutter 19916 186 28 4 DUS –
Prountjos 199145 57 20 – VNG –
Pulliam 199114 20 30 0 DUS Surgery
Lohr 199246 43 53 – DUS Surgery
Jorgensen 199347 44 23 – DUS –
Ascer 199525 20‡ 40 0 DUS Medical
Blumenberg 199748 213 (232 limbs) 8.6 0.93 DUS Medical
Bounameaux 199749 551 5.6 (95% CI 3.8–7.9) – VNG, DUS –
Verlato 199950 21 – 33.3 DUS, VQ, CXR
Murgia 199951 85 25.3 – DUS –
Unno 200217 51 11.8 7.8 DUS
DUS, Duplex ultrasound; VNG, venography; SFJ, saphenofemoral junction; VQ, ventilation perfusion lung scan; CXR, chest X ray.
* Free-floating thrombus in the common femoral vein extending from the SFJ was found during surgery.
† These thrombi were found in the perforator veins and nothing was mentioned about the deep veins.
‡ These patients were selected to have SFJ thrombosis.
Superficial Vein Thrombosis 13of STP, isolated perforating vein involvement was
never found.6 It is possible that thrombosis can extend
from the deep veins to the superficial ones, but this has
not been evaluated in any study.
Chengelis et al. 26 reported that 30 (11%) of 263
patients with saphenous thrombophlebitis had docu-
mented extension of thrombus into the deep veins. In
21 patients, the thrombus extended from the thigh
GSV into the common femoral vein (CFV). In three
patients, thrombus was extended from the thigh GSV
into the femoral vein through thigh perforators, three
patients had extension of a below knee saphenous
thrombus to the popliteal vein, and in another three
patients below-the-knee saphenous thrombi extended
via calf perforators to the tibioperoneal veins.
The prevalence of DVT in the presence of varicose
veins was reported in two small studies at 13% (5/39)
and 24.5% (10/41).44,47 DVT was no detected in the
absence of varicose veins but there were only three
limbs without them in each study. Berqvist and
Jaroszewski43 performed ascending venography in
56 patients with clinical evidence of STP, and DVTwas
found in nine patients. Eight of those nine patients did
not have varicose veins. Therefore, the prevalence of
DVT in patients with varicose veins was 2.6% in
contrast to 44% in those without (p!0.01). No patients
with varicose veins developed a malignancy on
follow-up whereas two patients without varicosities
were subsequently diagnosed with breast cancer and
polycythemia vera, respectively.
STP confined to above knee segment of the GSVwasassociated with 17–19% incidence of DVT and 4–5%
when STP did not extend above the knee.26,43
However, in another study the site of STP did not
point to the presence or absence of DVT.44 Propagation
of STP to the deep veins by serial DUS has been
documented in three studies (Table 3).14,26,48 These
data indicate that most patients with STP should have
their deep veins evaluated even if we accept the lowest
DVT prevalence of 5.6% shown by Bounameaux et al.49PE and STP
Given the low prevalence of this association, most of
the studies available in the literature include a small
number of patients. Gjores40 described five cases of PE
where the embolus originated from the GSV and no
evidence of DVT was found. Two of them were fatal
episodes after prostatectomy and the rest were small
and non-fatal. Zollinger et al.21 found a 1.5% rate of
fatal PE in patients with STP in his series. PE cases
have been reported with SSV involvement as well. An
18% rate of PE was reported when the thrombotic
process was located at the above-the-knee location in
the GSV; a 4% rate for SSV involvement and a 7%
propagation rate to the popliteal vein.6 The only
prospective study by Verlato et al.50 evaluated 21
consecutive patients with STP in the thigh segment of
GSV by DUS, chest X-ray and perfusion lung scanning,
regardless of their symptoms. They found seven
patients with high probability of PE (33%; 95% CI,
14.6–57). Only one of those patients was symptomatic.Eur J Vasc Endovasc Surg Vol 29, January 2005
Table 3. STP and development of venous thromboembolism
Author Patients (n) DVT (%) PE (%) Diagnosis Treatment
Pulliam 199114 20 15 – DUS Surgery
Chengelis 199626 263 11.4 R2.3 DUS; VQ Medical
Blumenberg 199748 232 limbs 2.6 – DUS Medical
DUS, Duplex ultrasound; VQ, ventilation perfusion lung scan.
L. Leon et al.14Unno et al.17 enrolled 51 consecutive patients with STP,
chosen among 710 patients referred for treatment of
varicose veins, in a risk assessment study. A 7.8% rate
of PE was found, all cases having involvement of the
GSV or SSV.
It is unclear whether PE associated with STP arises
from extension into the deep veins or from clot that
detaches while still in the superficial venous system.
This may be an important distinction, as surgical
ligation could prevent the latter case, but monitoring
with DUS should suffice if the former is more
common.Diagnostic approach of STP
The diagnosis of STP can be made on basis of clinical
or DUS data. STP is often easy to diagnose due to its
superficial location. Clinical features include the
presence of a warm, tender, palpable cord or nodule-
like structure following the course of a superficial vein.
But the diagnosis should not be limited to clinical
grounds only. The correlation between clinical exam
and surgical findings is poor. Clinical exam does not
reveal the true extent of STP; surgical exploration
shows often extension of the thrombotic process 5–
10 cm higher than the level that was clinically
diagnosed.40 We commonly find in our practice that
DUS often identifies a more proximal extent of STP
compared to clinical exam. DUS is recommended for
confirmation of diagnosis, for estimation of the extent
of thrombosis and for follow-up.11,20,26 Systematic
application of DUS has been criticized because of the
low incidence of DVT diagnosed. Bounameaux et al.49
retrospectively analysed a large number of medical
records of patients with STP over a 6-year period. This
study showed a 5.6% association of DVT in patients
with STP (31/551; 95% CI 3.8–7.9%), of which 26 cases
had proximal vein involvement. This paper suffers the
limitations of a retrospective design, and it may have
had important loss of data in follow-up.
STP cases can be divided in three broad categories,
based on DUS and clinical examination: those of a
short segment not associated with varicose veins; short
segment associated with varicosities; and extensive
saphenous thrombophlebitis.12 That stratification por-
tends important differences with regard to diagnosticEur J Vasc Endovasc Surg Vol 29, January 2005workup and management. Patients within the first
category often will have an underlying systemic
disease that should be investigated. Patients in the
second group need no further workup and their
treatment is symptomatic and surgery for varicosities
if needed. Clinical and DUS follow-up may still be
needed to confirm the absence of thrombus propa-
gation to the saphenous trunk. Patients in the third
group have an important association with DVTand PE
(Table 2)6,14,17,18,21,22,25,39–51 and the management
needs to be tailored accordingly.12
Thrombophilia screening has been recommended
to identify patients at risk for developing thromboem-
bolic complications.7,8,17,30,52 Some authorities perform
screening selectively based on the presence or absence
of risk factors.52–54 Once STP develops it is important
to differentiate whether this is confined to varicose
saphenous tributaries within the context of pre-
existing varicose vein disease or if it involves the
saphenous trunk, particularly the thigh segment. The
former situation seems not to require further investi-
gation, as it appears to be a localized event complicat-
ing varicose vein disease. However, clinical and DUS
follow-up may still be needed to confirm the absence
of thrombus propagation to the saphenous trunk. In
contrast, the latter situation seems to be more serious.
Most of the literature supports investigation by DUS in
order to accurately evaluate the extent of thrombus
and to exclude the presence of DVT.6,11,13,14,25,26,44–48,55
We recommend that the clinician should consider the
possibility of hypercoagulable states and malignancy
in patients without varicose veins who present with
STP.43Considerations in the management of STP
The treatment options available for STP include
ambulation, ES, anti-inflammatory agents, anticoagu-
lation and surgery (Table 4).18,19,21,22,24,25,27,28,34,40,41,46,
56–58 The evaluation of medical treatment for STP in
the literature yields conflicting results. This is due to
the lack of consistency with regards to the measured
end points, inadequate follow-up, limited evaluation
to rule out venous thromboembolism (VTE), small
number of patients studied and mainly due to the
retrospective nature of most of the studies.
Table 4. STP treatment
Author Patients (n) Treatment Measured outcome Results Follow-up (days)
Gjores 196240 40 Surgery VTE 8% PE –
Zollinger 196221 335* Bed restCeleva-
tionGAbx
Ambulation 19%% 3 days –
Anticoagulation 18%% 3 days
SurgeryGanticoa-
gulation
60%% 3 days
Williams 196456 92 Surgery VTE 0
Hafner 196441 324 Surgery (133) VTE PE 2.3% DVT 10.5% No follow-up
Medical (191) –
Husni 198222 221 Medical (82) PE 12%† 8–28
Surgery (139) 0
Lofgren 198118 163 Surgery VTE 1.2% PE; 4.3%
recurrent STP
365–4380 (median
1825)
Plate 198534 28 Surgery VTE, signs and
symptoms
14.3% Had persist-
ent symptoms
Lohr 199246 41 Surgery VTE one recurrent STP;
one with PE; two
with contralateral
DVT
Minimum 120
Titon 199457 117 LMWH Signs and symp-
toms
Greater improve-
ment with LMWH
56
NSAIDS
Ascer 199525 20 Anticoagulation DUS outcome of
thrombosis and PE
NZ13; 92.3%
improvement; 7.7%
without change
420
Hanson 199824 17 Medical (NSAIDS,
anticoagulation, ES)
DUS thrombus pro-
gression
NZ13; 46.2%
unchanged; 46.2%
worse; 7.6%
improved
?
Belcaro 199919 444 ES, surgery and
anticoagulation in
six combinations
DVT rate No difference 180
Thrombus exten-
sion
Higher with ES;
lowest with surgery
Beatty 200227 17 Emergent SFJ div-
ision
VTE 5.9% popliteal DVT;
no PE
60
Marchiori 200258 60 UFH low vs. high
dose (GNSAIDS)
VTE 20 vs. 3.3%,
respectively (pZ0.
05)
180
STENOX 200328 436 LMWH (two doses) STP extension and
VTE
Best 90
NSAIDS
ES
LMWH, lowmolecular weight heparin; NSAIDS, non-steroidal anti-inflammatory drugs; ES, elastic stockings; SFJ, saphenofemoral junction;
VTE, venous thromboembolism.
* These patients were known to have STP by clinical examination but the number of patients with concomitant DVTwas not known.
SurgeryGanticoagulation improved patients’ signs and symptoms. However, nowadays almost all patients ambulate and this does not seem
a good end point for evaluation. Five patients (1.5%) died from PE.
† Unknown whether these patients had concomitant DVT.
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pared unfavourably to anticoagulation in one trial, but
early ambulation was the measured end point.
Furthermore, antibiotics have no role in the manage-
ment of STP. Bacteriologic studies of thrombi obtained
in surgery that revealed a low incidence of microor-
ganisms and a low rate of wound infection reported in
most series speak against an infectious origin for
STP.41 The role of aspirin and NSAIDS in VTE are not
well defined. They decrease local pain and may add
anti-inflammatory benefits in STP. Non-steroidal anti-
inflammatory agents orally or as topical treatment,
local application of hirudoid and agents with enzy-
matic action have been used. These may have some
effect in the alleviation of pain and local inflammatory
signs but their efficacy is controversial.59–63Anticoagulation includes unfractionated heparin
(UFH), low molecular weight heparin (LMWH),
coumadin and recently pentasaccharides. LMWH
proved to be at least as effective and safe as UFH in
the treatment of DVT. Therefore, it could be a
reasonable alternative.64 The only randomised trial
enrolled 436 patients and compared ES, NSAIDS and
two doses of LMWH for 10 days. LMWH showed the
most favourably trend but it was only significant for
thrombus extension and not significant for develop-
ment of VTE.28
Interventional options include local thrombectomy,
vein ligation, excision or stripping and sclerotherapy.
Papers that analyse outcomes after surgery for STP
revealed a PE rate between 0 and 8% (Table 4).18,19,21,22,
24,25,27,28,34,40,41,46,56–58 This rate may be underestimatedEur J Vasc Endovasc Surg Vol 29, January 2005
L. Leon et al.16given that in most of those studies the diagnosis of PE
was made clinically in symptomatic patients only. The
reported rate of recurrent STP varies from 2 to 4.3%,
again probably underestimated due to presentation
bias. Selection of patients who have favourable risk/
benefit profiles for surgery is a problem as there are no
randomised control trials against anticoagulation.
ES should be used if tolerated in all cases of STP as
an adjunctive treatment regardless of the associated
conditions. Its use alone was associated with more
thrombi extension and VTE episodes when compared
with anticoagulation.28 In cases of STP located away
from the SFJ or the SPJ, or STP at lower levels, without
evidence of DVT, conservative management using ES,
NSAIDS or aspirin often suffice. In cases of concomi-
tant STP and DVT anticoagulation should be started.
When a thrombus is found in the SPJ or SFJ and
extends as free-floating in the CFV or popliteal veins,
removal of the thrombus during surgery is an equally
good treatment. If the thrombus is adherent or located
non-contiguously, anticoagulation is mandatory.
We emphasise that patients with STP require
follow-up, either clinical or with DUS. DUS should
be performed at about 7–10 days after the original
diagnosis to assess the extent and progression of STP.
If the symptoms worsen or if there is DUS or clinical
evidence of progression, anticoagulation or surgery
may be needed following the criteria described above.Final remarks and conclusions
STP is not always a benign condition. Although
generally benign if confined to varicose tributary
veins, there is evidence that involvement of the
GSV or SSV may be associated with more serious
conditions, notable DVT and PE. There is also a
significant association of STP with hypercoagulable
states. A relationship between STP and malignancy
has been reported but its strength has not been
determined. It is important to exclude concomitant
DVT at presentation. Therefore, its diagnosis should
not rely only on clinical evaluation but DUS should
be included.
Therapy for STP affecting varicose tributaries
should be conservative. For more serious STP affecting
the truncal GSV or SSV, we recommend anticoagula-
tion or early saphenous ligation. However, there are no
randomised studies to prove the superiority of any of
these options. In addition, the optimal length of the
anticoagulation treatment and the type of the anti-
coagulant drug are unknown.Eur J Vasc Endovasc Surg Vol 29, January 2005References
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